Projects per year
METHODS: We assessed blood-based DNA methylation at 13 CpGs in the APOE gene in 5828 participants from the Generation Scotland (GS) cohort. Using linear regression, we examined the relationship between APOE methylation, cognition, cholesterol, and the risks for AD and CVD.
RESULTS: DNA methylation at two CpGs was associated with the ratio/quotient of total cholesterol and HDL cholesterol, but not with cognition, or the risks of AD or CVD.
DISCUSSION: APOE methylation could be involved in the levels of blood cholesterol, but there is no evidence for the utility of APOE methylation as a biomarker for predicting AD or CVD.
|Journal||Alzheimer's and Dementia: Translational Research and Clinical Interventions|
|Early online date||27 Apr 2020|
|Publication status||E-pub ahead of print - 27 Apr 2020|
- DNA methylation
- Alzheimer’s disease
- cardiovascular disease
1/09/13 → 31/08/19